Advertisement

Renal Cancer pp 307-323 | Cite as

Management of Non-Clear Cell Renal Cell Carcinoma

  • Jeremy A. Ross
  • Pavlos Msaouel
  • Nizar M. TannirEmail author
Chapter

Abstract

Renal cell carcinoma comprises a large, heterogeneous group of tumors. Although clear cell renal cancer is the most common subtype, 20–25% of renal malignancies are of variant histology. Papillary renal cell carcinoma represents the most common non-clear cell histology, with unclassified, chromophobe, translocation, collecting duct, and renal medullary carcinoma making up the majority of the remainder. With the exception of collecting duct and renal medullary carcinoma, non-clear cell renal cell carcinomas tend to be resistant to chemotherapy. Immunotherapy tends to produce less responses among non-clear cell subtypes compared with clear cell renal cell carcinomas. The limited representation of non-clear cell renal cell carcinomas in large phase III randomized trials lends to uncertainty regarding the benefit of targeted therapy in this group.

Although anti-vascular endothelial growth factor (VEGF) agents, mammalian target of rapamycin (mTOR) inhibitors, and immune checkpoint inhibitors (ICIs) have made a large impact in the management of advanced clear cell renal cell carcinoma, their efficacy in non-clear cell histologies is still being defined. As we learn more about these tumor types, new subtypes of non-clear cell kidney cancer and new genetic abnormalities are being discovered. This improved understanding can lead to better treatments in the future for our patients.

Keywords

Non-clear cell renal cell carcinoma Papillary Renal medullary carcinoma Collecting duct carcinoma Translocation carcinoma Chromophobe Unclassified renal cancer Chemotherapy VEGF mTOR 

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRefGoogle Scholar
  2. 2.
    Kamel MH, Moore PC, Bissada NK, Heshmat SM. Potential years of life lost due to urogenital cancer in the United States: trends from 1972 to 2006 based on data from the SEER database. J Urol. 2012;187(3):868–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefGoogle Scholar
  4. 4.
    Zini L, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Antebi E, et al. Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer. 2009;115(7):1465–71.CrossRefPubMedGoogle Scholar
  5. 5.
    Antonelli A, Ficarra V, Bertini R, Carini M, Carmignani G, Corti S, et al. Elective partial nephrectomy is equivalent to radical nephrectomy in patients with clinical T1 renal cell carcinoma: results of a retrospective, comparative, multi-institutional study. BJU Int. 2012;109(7):1013–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Miller DC, Schonlau M, Litwin MS, Lai J, Saigal CS. Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer. 2008;112(3):511–20.CrossRefPubMedGoogle Scholar
  7. 7.
    Blom JH, van Poppel H, Marechal JM, Jacqmin D, Schroder FH, de Prijck L, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 2009;55(1):28–34.CrossRefPubMedGoogle Scholar
  8. 8.
    Capitanio U, Becker F, Blute ML, Mulders P, Patard JJ, Russo P, et al. Lymph node dissection in renal cell carcinoma. Eur Urol. 2011;60(6):1212–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol. 1990;143(3):468–73; discussion 73–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Montie JE, Stewart BH, Straffon RA, Banowsky LH, Hewitt CB, Montague DK. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol. 1977;117(3):272–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol. 1997;158(5):1675–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Russo P, Synder M, Vickers A, Kondagunta V, Motzer R. Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. TheScientificWorldJOURNAL. 2007;7:768–78.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.CrossRefGoogle Scholar
  14. 14.
    Mejean A, Roupret M, Larousserie F, Hopirtean V, Thiounn N, Dufour B. Is there a place for radical nephrectomy in the presence of metastatic collecting duct (Bellini) carcinoma? J Urol. 2003;169(4):1287–90.CrossRefPubMedGoogle Scholar
  15. 15.
    Vaeth JM. Proceedings: cancer of the kidney--radiation therapy and its indications in non-Wilms’ tumors. Cancer. 1973;32(5):1053–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Siva S, Kothari G, Muacevic A, Louie AV, Slotman BJ, Teh BS, et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol. 2017;14(9):549–63.CrossRefPubMedGoogle Scholar
  17. 17.
    Onufrey V, Mohiuddin M. Radiation therapy in the treatment of metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys. 1985;11(11):2007–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys. 1987;13(5):665–72.CrossRefPubMedGoogle Scholar
  19. 19.
    Reuter VE. The pathology of renal epithelial neoplasms. Semin Oncol. 2006;33(5):534–43.CrossRefPubMedGoogle Scholar
  20. 20.
    Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865–75.CrossRefPubMedGoogle Scholar
  21. 21.
    de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25(3):275–84.CrossRefPubMedGoogle Scholar
  22. 22.
    Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, et al. Outcomes of patients with renal cell carcinoma and Sarcomatoid dedifferentiation treated with nephrectomy and systemic therapies: comparison between the cytokine and targeted therapy eras. J Urol. 2017;198(3):530–7.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28(4):435–41.CrossRefPubMedGoogle Scholar
  24. 24.
    Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23(12):2763–71.CrossRefPubMedGoogle Scholar
  25. 25.
    Beck SD, Patel MI, Snyder ME, Kattan MW, Motzer RJ, Reuter VE, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2004;11(1):71–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Amin MB, Paner GP, Alvarado-Cabrero I, Young AN, Stricker HJ, Lyles RH, et al. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol. 2008;32(12):1822–34.CrossRefPubMedGoogle Scholar
  27. 27.
    Amin MB, Amin MB, Tamboli P, Javidan J, Stricker H, de-Peralta Venturina M, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26(3):281–91.CrossRefPubMedGoogle Scholar
  28. 28.
    Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;183(4):1309–15.CrossRefPubMedGoogle Scholar
  29. 29.
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–40.CrossRefGoogle Scholar
  30. 30.
    Ronnen EA, Kondagunta GV, Ishill N, Spodek L, Russo P, Reuter V, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer. 2006;107(11):2617–21.CrossRefPubMedGoogle Scholar
  31. 31.
    Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.CrossRefGoogle Scholar
  32. 32.
    Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res. 2004;10(18 Pt 2):6290s–5s.CrossRefPubMedGoogle Scholar
  33. 33.
    Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22(24):4991–5004.CrossRefPubMedGoogle Scholar
  34. 34.
    Lubensky IA, Schmidt L, Zhuang Z, Weirich G, Pack S, Zambrano N, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol. 1999;155(2):517–26.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68–73.CrossRefPubMedGoogle Scholar
  36. 36.
    Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 2006;6(8):637–45.CrossRefPubMedGoogle Scholar
  37. 37.
    Sweeney P, El-Naggar AK, Lin SH, Pisters LL. Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol. 2002;168(1):51–5.CrossRefPubMedGoogle Scholar
  38. 38.
    Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135–45.CrossRefPubMedGoogle Scholar
  39. 39.
    Pignot G, Elie C, Conquy S, Vieillefond A, Flam T, Zerbib M, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology. 2007;69(2):230–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Toro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73(1):95–106.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Koski TA, Lehtonen HJ, Jee KJ, Ninomiya S, Joosse SA, Vahteristo P, et al. Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer. Genes Chromosomes Cancer. 2009;48(7):544–51.CrossRefPubMedGoogle Scholar
  42. 42.
    Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, Lucin K, et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res. 2007;67(7):3171–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Teh BT, Yang XJ, Tan M, Kim HL, Stadler W, Vogelzang NG, et al. Gene expression profiling identifies two distinct papillary renal cell carcinoma (RCC) subgroups of contrasting prognosis. J Clin Oncol. 2006;24(18_suppl):4503.Google Scholar
  44. 44.
    Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.CrossRefGoogle Scholar
  45. 45.
    Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010;116(5):1272–80.CrossRefPubMedGoogle Scholar
  46. 46.
    Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.CrossRefGoogle Scholar
  47. 47.
    Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10(8):757–63.CrossRefPubMedGoogle Scholar
  49. 49.
    Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012;62(6):1013–9.CrossRefPubMedGoogle Scholar
  50. 50.
    Lee JL, Ahn JH, Lim HY, Park SH, Lee SH, Kim TM, et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol. 2012;23(8):2108–14.CrossRefPubMedGoogle Scholar
  51. 51.
    Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Medical Oncol (Northwood, London, England). 2009;26(2):202–9.CrossRefGoogle Scholar
  52. 52.
    Yang S, de Souza P, Alemao E, Purvis J. Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br J Cancer. 2010;102(10):1456–60.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem. 2006;281(36):25903–14.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Perera AD, Kleymenova EV, Walker CL. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clin Cancer Res. 2000;6(4):1518–23.PubMedGoogle Scholar
  55. 55.
    Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL−/− renal cancer. Cancer Res. 2005;65(12):5221–30.CrossRefPubMedGoogle Scholar
  56. 56.
    Gordon MS, Hussey M, Nagle RB, Lara PN Jr, Mack PC, Dutcher J, et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009;27(34):5788–93.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Dawson NA, Guo C, Zak R, Dorsey B, Smoot J, Wong J, et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res. 2004;10(23):7812–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, et al. Everolimus versus Sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69(5):866–74.CrossRefGoogle Scholar
  59. 59.
    Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–88.CrossRefPubMedGoogle Scholar
  60. 60.
    Park I, Lee SH, Lee JL. A multicenter phase II trial of Axitinib in patients with recurrent or metastatic non-clear-cell renal cell carcinoma who had failed prior treatment with Temsirolimus. Clin Genitourin Cancer. 2018;16:e997.CrossRefPubMedGoogle Scholar
  61. 61.
    Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31(2):181–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Srinivasan R, Bottaro DP, Choueiri TK, Vaishampayan UN, Rosenberg JE, Logan T, et al. Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: results from a multicenter phase II study (MET111644). J Clin Oncol. 2012;30(5_suppl):372.CrossRefGoogle Scholar
  63. 63.
    Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, et al. Biomarker-based phase II trial of Savolitinib in patients with advanced papillary renal cell cancer. J Clin Oncol. 2017;35(26):2993–3001.CrossRefPubMedGoogle Scholar
  64. 64.
    National Cancer I. Cabozantinib S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer 2020 [updated March 1. Available from: https://ClinicalTrials.gov/show/NCT02761057.
  65. 65.
    Tsimafeyeu I, Demidov L, Kharkevich G, Petenko N, Galchenko V, Sinelnikov I, et al. Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma. Am J Clin Oncol. 2012;35(3):251–4.CrossRefPubMedGoogle Scholar
  66. 66.
    Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF. Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer. 2009;7(1):39–42.CrossRefPubMedGoogle Scholar
  67. 67.
    Fleming S. Distal nephron neoplasms. Semin Diagn Pathol. 2015;32(2):114–23.CrossRefPubMedGoogle Scholar
  68. 68.
    Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene. 2003;22(6):847–52.CrossRefPubMedGoogle Scholar
  69. 69.
    Speicher MR, Schoell B, du Manoir S, Schrock E, Ried T, Cremer T, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 1994;145(2):356–64.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Akhtar M, Kardar H, Linjawi T, McClintock J, Ali MA. Chromophobe cell carcinoma of the kidney. A clinicopathologic study of 21 cases. Am J Surg Pathol. 1995;19(11):1245–56.CrossRefPubMedGoogle Scholar
  71. 71.
    Haake SM, Rathmell WK. Renal cancer subtypes: should we be lumping or splitting for therapeutic decision making? Cancer. 2017;123(2):200–9.CrossRefPubMedGoogle Scholar
  72. 72.
    Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014;26(3):319–30.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell. 2002;2(2):157–64.CrossRefPubMedGoogle Scholar
  74. 74.
    Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A. 2006;103(42):15552–7.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Kato I, Iribe Y, Nagashima Y, Kuroda N, Tanaka R, Nakatani Y, et al. Fluorescent and chromogenic in situ hybridization of CEN17q as a potent useful diagnostic marker for Birt-Hogg-Dube syndrome-associated chromophobe renal cell carcinomas. Hum Pathol. 2016;52:74–82.CrossRefPubMedGoogle Scholar
  76. 76.
    Schmidt LS, Nickerson ML, Warren MB, Glenn GM, Toro JR, Merino MJ, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet. 2005;76(6):1023–33.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Khoo SK, Kahnoski K, Sugimura J, Petillo D, Chen J, Shockley K, et al. Inactivation of BHD in sporadic renal tumors. Cancer Res. 2003;63(15):4583–7.PubMedGoogle Scholar
  78. 78.
    Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26(1):127–31.CrossRefPubMedGoogle Scholar
  79. 79.
    Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT, et al. Phase II trial and correlative genomic analysis of Everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2016;34(32):3846–53.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Paule B, Brion N. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy. Anticancer Res. 2011;31(1):331–3.PubMedGoogle Scholar
  81. 81.
    Matrana MR, Ng C, Rao P, Lim ZD, Tannir NM. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report. Clin Genitourin Cancer. 2011;9(2):137–9.CrossRefPubMedGoogle Scholar
  82. 82.
    Marur S, Eliason J, Heilbrun LK, Dickow B, Smith DW, Baranowski K, et al. Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma. Urology. 2008;72(4):898–902.CrossRefPubMedGoogle Scholar
  83. 83.
    Zhong M, De Angelo P, Osborne L, Paniz-Mondolfi AE, Geller M, Yang Y, et al. Translocation renal cell carcinomas in adults: a single-institution experience. Am J Surg Pathol. 2012;36(5):654–62.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Cajaiba MM, Dyer LM, Geller JI, Jennings LJ, George D, Kirschmann D, et al. The classification of pediatric and young adult renal cell carcinomas registered on the Children’s Oncology Group (COG) protocol AREN03B2 after focused genetic testing. Cancer. 2018;124:3381.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Argani P, Hicks J, De Marzo AM, Albadine R, Illei PB, Ladanyi M, et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol. 2010;34(9):1295–303.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Clark J, Lu YJ, Sidhar SK, Parker C, Gill S, Smedley D, et al. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene. 1997;15(18):2233–9.CrossRefPubMedGoogle Scholar
  87. 87.
    Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, Newbury R, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001;159(1):179–92.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27(6):750–61.CrossRefPubMedGoogle Scholar
  89. 89.
    Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005;29(2):230–40.CrossRefPubMedGoogle Scholar
  90. 90.
    Skala SL, Xiao H, Udager AM, Dhanasekaran SM, Shukla S, Zhang Y, et al. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. Mod Pathol. 2018;31(1):179–97.CrossRefPubMedGoogle Scholar
  91. 91.
    Davis IJ, Hsi BL, Arroyo JD, Vargas SO, Yeh YA, Motyckova G, et al. Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A. 2003;100(10):6051–6.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Kuiper RP, Schepens M, Thijssen J, van Asseldonk M, van den Berg E, Bridge J, et al. Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. Hum Mol Genet. 2003;12(14):1661–9.CrossRefPubMedGoogle Scholar
  93. 93.
    Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol. 2013;37(10):1469–89.CrossRefGoogle Scholar
  94. 94.
    Argani P. MiT family translocation renal cell carcinoma. Semin Diagn Pathol. 2015;32(2):103–13.CrossRefPubMedGoogle Scholar
  95. 95.
    Malouf GG, Camparo P, Molinie V, Dedet G, Oudard S, Schleiermacher G, et al. Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol. 2011;185(1):24–9.CrossRefPubMedGoogle Scholar
  96. 96.
    Xu L, Yang R, Gan W, Chen X, Qiu X, Fu K, et al. Xp11.2 translocation renal cell carcinomas in young adults. BMC Urol. 2015;15:57.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010;116(22):5219–25.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol. 2010;21(9):1834–8.CrossRefPubMedGoogle Scholar
  99. 99.
    Davis CJ Jr, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol. 1995;19(1):1–11.CrossRefPubMedGoogle Scholar
  100. 100.
    Sathyamoorthy K, Teo A, Atallah M. Renal medullary carcinoma in a patient with sickle-cell disease. Nat Clin Pract Urol. 2006;3(5):279–83. quiz 89.CrossRefPubMedGoogle Scholar
  101. 101.
    Baig MA, Lin YS, Rasheed J, Mittman N. Renal medullary carcinoma. J Natl Med Assoc. 2006;98(7):1171–4.PubMedPubMedCentralGoogle Scholar
  102. 102.
    Msaouel P, Tannir NM, Walker CL. A model linking sickle cell Hemoglobinopathies and SMARCB1 loss in renal medullary carcinoma. Clin Cancer Res. 2018;24(9):2044–9.CrossRefPubMedGoogle Scholar
  103. 103.
    Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, et al. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017;120(6):782–92.CrossRefPubMedGoogle Scholar
  104. 104.
    Margol AS, Judkins AR. Pathology and diagnosis of SMARCB1-deficient tumors. Cancer Genet. 2014;207(9):358–64.CrossRefPubMedGoogle Scholar
  105. 105.
    Cheng JX, Tretiakova M, Gong C, Mandal S, Krausz T, Taxy JB. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol. 2008;21(6):647–52.CrossRefPubMedGoogle Scholar
  106. 106.
    Sirohi D, Smith SC, Ohe C, Colombo P, Divatia M, Dragoescu E, et al. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma. Hum Pathol. 2017;67:134–45.CrossRefPubMedGoogle Scholar
  107. 107.
    Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, et al. Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase-deficient renal cell carcinoma. Am J Surg Pathol. 2018;42(3):279–92.CrossRefPubMedGoogle Scholar
  108. 108.
    Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee C, et al. Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma. Clin Genitourin Cancer. 2018;17(1):1–6.CrossRefPubMedGoogle Scholar
  109. 109.
    Strouse JJ, Spevak M, Mack AK, Arceci RJ, Small D, Loeb DM. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer. 2005;44(4):407–11.CrossRefPubMedGoogle Scholar
  110. 110.
    Noguera-Irizarry WG, Hibshoosh H, Papadopoulos KP. Renal medullary carcinoma: case report and review of the literature. Am J Clin Oncol. 2003;26(5):489–92.CrossRefPubMedGoogle Scholar
  111. 111.
    Rathmell WK, Monk JP. High-dose-intensity MVAC for advanced renal medullary carcinoma: report of three cases and literature review. Urology. 2008;72(3):659–63.CrossRefPubMedGoogle Scholar
  112. 112.
    Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Genitales) study. J Urol. 2007;177(5):1698–702.CrossRefPubMedGoogle Scholar
  113. 113.
    Schaeffer EM, Guzzo TJ, Furge KA, Netto G, Westphal M, Dykema K, et al. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int. 2010;106(1):62–5.CrossRefPubMedGoogle Scholar
  114. 114.
    Martinez Chanza N, Bossé D, Bilen M, Geynisman D, Balakrishnan A, Jain R, Bowman I, Zakharia Y, Narayan V, Beuselinck B, Agarwal N. Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): a retrospective multicenter analysis. J Clin Oncol. 2018;36:4579.CrossRefGoogle Scholar
  115. 115.
    Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8(8):2505–11.PubMedGoogle Scholar
  116. 116.
    Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol. 2004;22(18):3720–5.CrossRefPubMedGoogle Scholar
  117. 117.
    Ronnen EA, Kondagunta GV, Motzer RJ. Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol. 2006;24(9):e14.CrossRefPubMedGoogle Scholar
  118. 118.
    Carden MA, Smith S, Meany H, Yin H, Alazraki A, Rapkin LB. Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: two cases. Pediatr Blood Cancer. 2017;64(7)Google Scholar
  119. 119.
    Ixazomib, Gemcitabine, and Doxorubicin in Treating Participants With Locally Advanced or Metastatic Kidney Cancer. ClinicalTrials.gov Identifier: NCT03587662.Google Scholar
  120. 120.
    Ansari J, Fatima A, Chaudhri S, Bhatt RI, Wallace M, James ND. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. Onkologie. 2009;32(1–2):44–6.PubMedGoogle Scholar
  121. 121.
    Miyake H, Haraguchi T, Takenaka A, Fujisawa M. Metastatic collecting duct carcinoma of the kidney responded to sunitinib. Int J Clin Oncol. 2011;16(2):153–5.CrossRefPubMedGoogle Scholar
  122. 122.
    Ferlicot S, Allory Y, Comperat E, Mege-Lechevalier F, Dimet S, Sibony M, et al. Mucinous tubular and spindle cell carcinoma: a report of 15 cases and a review of the literature. Virchows Arch. 2005;447(6):978–83.CrossRefPubMedGoogle Scholar
  123. 123.
    Zhao M, He XL, Teng XD. Mucinous tubular and spindle cell renal cell carcinoma: a review of clinicopathologic aspects. Diagn Pathol. 2015;10:168.CrossRefPubMedPubMedCentralGoogle Scholar
  124. 124.
    Hes O, Hora M, Perez-Montiel DM, Suster S, Curik R, Sokol L, et al. Spindle and cuboidal renal cell carcinoma, a tumour having frequent association with nephrolithiasis: report of 11 cases including a case with hybrid conventional renal cell carcinoma/spindle and cuboidal renal cell carcinoma components. Histopathology. 2002;41(6):549–55.CrossRefPubMedGoogle Scholar
  125. 125.
    Paner GP, Srigley JR, Radhakrishnan A, Cohen C, Skinnider BF, Tickoo SK, et al. Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution. Am J Surg Pathol. 2006;30(1):13–9.CrossRefPubMedGoogle Scholar
  126. 126.
    Shen SS, Ro JY, Tamboli P, Truong LD, Zhai Q, Jung SJ, et al. Mucinous tubular and spindle cell carcinoma of kidney is probably a variant of papillary renal cell carcinoma with spindle cell features. Ann Diagn Pathol. 2007;11(1):13–21.CrossRefPubMedGoogle Scholar
  127. 127.
    Cossu-Rocca P, Eble JN, Delahunt B, Zhang S, Martignoni G, Brunelli M, et al. Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma. Mod Pathol. 2006;19(4):488–93.CrossRefPubMedGoogle Scholar
  128. 128.
    Mehra R, Vats P, Cieslik M, Cao X, Su F, Shukla S, et al. Biallelic alteration and dysregulation of the hippo pathway in mucinous tubular and spindle cell carcinoma of the kidney. Cancer Discov. 2016;6(11):1258–66.CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    Thway K, du Parcq J, Larkin JM, Fisher C, Livni N. Metastatic renal mucinous tubular and spindle cell carcinoma. Atypical behavior of a rare, morphologically bland tumor. Ann Diagn Pathol. 2012;16(5):407–10.CrossRefPubMedGoogle Scholar
  130. 130.
    Furuya S, Manabe O, Nanbu T, Yamashita N, Shinnno Y, Kasai K, et al. Renal mucinous tubular and spindle cell carcinoma shows a high uptake on (18)F-FDG PET/CT. Internal Med (Tokyo, Japan). 2018;57(8):1131–4.CrossRefGoogle Scholar
  131. 131.
    Pillay N, Ramdial PK, Cooper K, Batuule D. Mucinous tubular and spindle cell carcinoma with aggressive histomorphology–a sarcomatoid variant. Hum Pathol. 2008;39(6):966–9.CrossRefPubMedGoogle Scholar
  132. 132.
    Dhillon J, Amin MB, Selbs E, Turi GK, Paner GP, Reuter VE. Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change. Am J Surg Pathol. 2009;33(1):44–9.CrossRefPubMedGoogle Scholar
  133. 133.
    Zhou M, Yang XJ, Lopez JI, Shah RB, Hes O, Shen SS, et al. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification. Am J Surg Pathol. 2009;33(12):1840–9.CrossRefPubMedGoogle Scholar
  134. 134.
    Amin MB, MacLennan GT, Gupta R, Grignon D, Paraf F, Vieillefond A, et al. Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol. 2009;33(3):384–92.CrossRefPubMedGoogle Scholar
  135. 135.
    Mego M, Sycova-Mila Z, Rejlekova K, Rychly B, Obertova J, Rajec J, et al. Sunitinib in the treatment of tubulocystic carcinoma of the kidney. A case report. Ann Oncol. 2008;19(9):1655–6.CrossRefPubMedGoogle Scholar
  136. 136.
    Bhullar JS, Thamboo T, Esuvaranathan K. Unique case of tubulocystic carcinoma of the kidney with sarcomatoid features: a new entity. Urology. 2011;78(5):1071–2.CrossRefPubMedGoogle Scholar
  137. 137.
    Jung SJ, Chung JI, Park SH, Ayala AG, Ro JY. Thyroid follicular carcinoma-like tumor of kidney: a case report with morphologic, immunohistochemical, and genetic analysis. Am J Surg Pathol. 2006;30(3):411–5.CrossRefPubMedGoogle Scholar
  138. 138.
    Sterlacci W, Verdorfer I, Gabriel M, Mikuz G. Thyroid follicular carcinoma-like renal tumor: a case report with morphologic, immunophenotypic, cytogenetic, and scintigraphic studies. Virchows Arch. 2008;452(1):91–5.CrossRefPubMedGoogle Scholar
  139. 139.
    Amin MB, Gupta R, Ondrej H, McKenney JK, Michal M, Young AN, et al. Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm. Am J Surg Pathol. 2009;33(3):393–400.CrossRefPubMedGoogle Scholar
  140. 140.
    Dhillon J, Tannir NM, Matin SF, Tamboli P, Czerniak BA, Guo CC. Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol. 2011;42(1):146–50.CrossRefPubMedGoogle Scholar
  141. 141.
    Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol. 2007;178(5):1896–900.CrossRefPubMedGoogle Scholar
  142. 142.
    Abel EJ, Wood CG. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol. 2009;6(7):375–83.CrossRefPubMedGoogle Scholar
  143. 143.
    Marchioni M, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, et al. Survival after Cytoreductive nephrectomy in metastatic non-clear cell renal cell carcinoma patients: a population-based study. Eur Urol Focus. 2019;5(3):488–96.Google Scholar
  144. 144.
    Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer. 2007;110(11):2468–77.CrossRefPubMedGoogle Scholar
  145. 145.
    Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother (Hagerstown, Md : 1997). 2005;28(5):488–95.CrossRefGoogle Scholar
  146. 146.
    Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.CrossRefPubMedPubMedCentralGoogle Scholar
  147. 147.
    Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Jeremy A. Ross
    • 1
  • Pavlos Msaouel
    • 2
  • Nizar M. Tannir
    • 3
    Email author
  1. 1.Cancer Medicine, Fellowship Program, UT MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Genitourinary Medical OncologyUT MD Anderson Cancer CenterHoustonUSA
  3. 3.Genitourinary Medical Oncology, UT MD Anderson Cancer CenterHoustonUSA

Personalised recommendations